AM-679 (part of the
AM cannabinoid series) is a drug that acts as a moderately potent
agonist for the
cannabinoid receptors, with a
Ki of 13.5 nM at
CB1 and 49.5 nM at
CB2.[1] AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands that are now widely used in research, including the potent CB1 agonists
AM-694 and
AM-2233, and the selective CB2 agonist
AM-1241.[2] AM-679 was first identified as having been sold as a
cannabinoiddesigner drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole.[3]
^Deng H (2000). Design and synthesis of selective cannabinoid receptor ligands: Aminoalkylindole and other heterocyclic analogs (PhD Dissertation). University of Connecticut.
ProQuest304624325.
^Jankovics P, Váradi A, Tölgyesi L, Lohner S, Németh-Palotás J, Balla J (January 2012). "Detection and identification of the new potential synthetic cannabinoids 1-pentyl-3-(2-iodobenzoyl)indole and 1-pentyl-3-(1-adamantoyl)indole in seized bulk powders in Hungary". Forensic Science International. 214 (1–3): 27–32.
doi:
10.1016/j.forsciint.2011.07.011.
PMID21813254.